Dainippon Sumitomo Obtains Lunesta Patent Extension; Pediatric Studies To Resume
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Dec. 18 announced U.S. subsidiary Sepracor obtained a two-year patent term extension for insomnia drug Lunesta (eszopiclone) from the U.S. Patent and Trade Office